Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy

Journal of Cutaneous Pathology

Volumn 43, Issue 4, 2016, Pages 339-346

  Schaberg, Kurt B ^a   Novoa, Roberto A ^a   Wakelee, Heather A ^a   Kim, Jinah ^a   Cheung, Christine ^a   Srinivas, Sandhya ^a   Kwong, Bernice Y ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

drug reaction; immunotherapy; lichenoid reaction; programmed death 1; programmed death ligand 1

Indexed keywords

ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

AGED; ANTAGONISTS AND INHIBITORS; CASE REPORT; CHEMICALLY INDUCED; FEMALE; HUMAN; LICHENOID ERUPTION; MALE; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LICHENOID ERUPTIONS; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84963723011     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.12666     Document Type: Article

References (13)

1. Brower V,. Checkpoint blockade immunotherapy for cancer comes of age. J Natl Cancer Inst 2015; 107: 2.
2. Topalian SL, Hodi FS, Brahmer JR, et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443.
3. Hodi FS, O'Day SJ, McDermott DF, et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711.
4. Brahmer JR, Tykodi SS, Chow LQ, et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455.
5. Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME,. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2013; 69: e121.
6. Joseph RW, Cappel M, Goedjen B, et al., Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res 2015; 3: 18.
7. Deguchi M, Aiba S, Ohtani H, Nagura H, Tagami H,. Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease. Arch Dermatol Res 2002; 294: 297.
8. Woo SR, Corrales L, Gajewski TF,. Innate immune recognition of cancer. Annu Rev Immunol 2015; 33: 445.
9. Rodriguez Pinilla SM, Roncador G, Rodriguez-Peralto JL, et al., Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol 2009; 33: 81.
10. Ally MS, Prasad Hunasehally RY, Rodriguez-Justo M, et al., Evaluation of follicular T-helper cells in primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma and dermatitis. J Cutan Pathol 2013; 40: 1006.
11. Fujimura T, Okuyama R, Ito Y, Aiba S,. Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides. Br J Dermatol 2008; 158: 1256.
12. Du GH, Qin XP, Li Q, Zhou YM, Shen XM, Tang GY,. The high expression level of programmed death-1 ligand 2 in oral lichen planus and the possible costimulatory effect on human T cells. J Oral Pathol Med 2011; 40: 525.
13. Hua C, Boussemart L, Mateus C, et al., Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016; 152: 45.